Stuart Therapeutics Spotlights Topical RP Program - Summary - MDSpire

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

  • By

  • Eric Schlumpf

  • July 15, 2026

  • 2 min

Share

Objective:

To discuss a new inherited retinal disease program based on a collagen mimetic peptide platform for retinitis pigmentosa.

Approach:
  • Program Overview: The program is designed as a topical therapy for retinitis pigmentosa, focusing on safety and efficacy for younger patients.
  • Mechanism of Action: The therapy aims to provide neuroprotective effects, reduce inflammation, and improve the health of the posterior retina.
  • Preclinical Studies: New data from preclinical studies in nonhuman primates show effective topical drop penetration throughout the posterior retina.
Key Findings:
  • The topical therapy demonstrates penetration into the critical retinal extracellular matrix region.
  • The program is in preclinical development stages.
Interpretation:

Conclusion:

Original Source(s)

Stuart Therapeutics Spotlights Topical RP Program

  • by Eric Schlumpf

  • July 15, 2026

Related Content

New Target for Uveitis Therapy

Could targeting cGAS-STING represent a new treatment avenue for uveitis?

  • May 21, 2026

  • 3 min
Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.